Hamostaseologie 1989; 09(04): 204-208
DOI: 10.1055/s-0038-1655271
Originalarbeiten
Schattauer GmbH

Hirudin als potentielles Antikoagulans zur Prävention der Rethrombosierung nach intrakoronarer Lyse und Angioplastie

F. Markwardt
1   Institut für Pharmakologie und Toxikologie der Medizinischen Akademie Erfurt
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2018 (online)

 

 
  • LITERATUR

  • 1 Bagdy D, Barabas E, Graf L, Peterson T E, Magnusson S. Hirudin. Meth Enzymol 1976; 45: 669-78.
  • 2 Baskova I P, Cherkesova D U, Mosolov V V. Hirudin from leech heads and whole leeches and “pseudo-hirudin” from leech bodies. Thromb Res 1983; 30: 459-67.
  • 3 Bichler J, Fichtl B, Siebeck M, Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneimittelforschung 1988; 38: 704-10.
  • 4 Bucha E, Nowak G, Markwardt E. Prevention of experimental coronary thrombosis by hirudin. Folia Haematol 1988; 115: 52-58.
  • 5 Dodt J, Machleidt W, Seemüller U, Maschler R, Fritz H. Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA. Biol Chem Hoppe-Seyler 1986; 367: 803-11.
  • 6 Dodt J, Seemüller U, Maschler R, Fritz H. The complete covalent structure of hirudin. Biol Chem Hoppe-Seyler 1985; 366: 379-85.
  • 7 Glusa E, Wolfram U. The contractile response of vascular smooth muscle to thrombin and its inhibition by thrombin inhibitors. Folia Haematol 1988; 115: 94-100.
  • 8 Glusa E, Urban U. Studies in platelet functions in hirudin plasma. Folia Haematol 1988; 115: 88-93.
  • 9 Hauptmann J, Brüggener E. Influence of hirudin on the consumption of antithrombin III in experimental DIC. Folia Haematol 1988; 115: 83-87.
  • 10 Hoffmann A, Markwardt F. Inhibition of the thrombin-platelet reaction by hirudin. Haemostasis 1984; 14: 164-69.
  • 11 Ishikawa A, Hafter R, Seemüller U, Gokel J M, Graeff H. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC). Thromb Res 1980; 19: 351-58.
  • 12 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin. Folia Haematol 1988; 115: 41-46.
  • 13 Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost. (in press).
  • 14 Klöcking H P, Güttner J, Fink E. Toxicological studies with recombinant hirudin. Folia Haematol 1988; 115: 75-82.
  • 15 Klöcking H P, Markwardt F. Influence of recombinant hirudin on the thrombogenicity of prothrombin complex concentrates. Pharmazie 1989; 44: 341-42.
  • 16 Krupinski K, Breddin H K, Markwardt F, Haarmann W. Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis. Haemostasis 1989; 19: 74-82.
  • 17 Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften 1955; 42: 537-38.
  • 18 Markwardt F. Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo. Naturwissenschaften 1956; 43: 111.
  • 19 Markwardt F. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins. NaunynSchmiedebergs Arch Pharmacol 1956; 229: 389-99.
  • 20 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. HoppeSeyler’s Z Physiol Chem 1957; 308: 147-56.
  • 21 Markwardt F. Versuche zur pharmakologischen Charakterisierung des Hirudins. Naunyn-Schmiedebergs Arch Pharmacol 1958; 234: 516-29.
  • 22 Markwardt F. Hirudin as an inhibitor of thrombin. In: Meth Enzymol 19: Proteolytic Enzymes. Perlmann G E, Lorand L. (eds). New York, London: Academic Press; 1970: 924-32.
  • 23 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent. Biomed Biochim Acta 1985; 44: 1007-13.
  • 24 Markwardt F. Antithrombotic action of hirudin in experimental coronary thrombosis (Abstr). European Society of Cardiology “Thrombosis and Platelets”, Tours. 1986
  • 25 Markwardt F. Pharmacological approaches to thrombin regulation. Ann NY Acad Sci 1986; 485: 204-14.
  • 26 Markwardt F. Prevention of coronary thrombosis by hirudin. In: Cardiovascular Pharmacology ’87.. Papp J G. (ed). Budapest: Akademiai Kiado; 1987: 449-56.
  • 27 Markwardt F. Pharmacology of recombinant hirudin (Abst 0134). Xth International Congress of Pharmacology, Sydney. 1987
  • 28 Markwardt F. Anticoagulants after Thrombolysis. In: Reperfusion and Revascularisation in Acute Myocardial Infarction. Schettler G, Jennings R B, Rapoport E, Wenger N K, Bernhardt R. (eds). Berlin Heidelberg: Springer; 1988: 137-43.
  • 29 Markwardt F. Biochemistry and pharmacology of hirudin. In: Hemostasis and Animal Venoms. Pirkle H, Markland Jr F S. (eds). New York, Basel: Dekker; 1988: 255-69.
  • 30 Markwardt F. The comeback of hirudin an old-established anticoagulant agent. Folia Haematol 1988; 115: 10-23.
  • 31 Markwardt F. Pharmacology of selective thrombin inhibitors. Nouv Rev Fr Hematol 1988; 30: 161-5.
  • 32 Markwardt F, Bernstein K, Drawert J, Eger H, Klöcking H P, Sedlarik K, Vollmar V, Wilde J. Thrombolytische Behandlung einer experimentellen Koronarthrombose mit Streptokinase. Exp Pathol 1977; 14: 76-88.
  • 33 Markwardt F, Fink E, Kaiser B, Klöcking H P, Nowak G, Richter M, Stürzebecher J. Pharmacological survey of recombinant hirudin. Pharmazie 1988; 43: 202-7.
  • 34 Markwardt F, Hauptmann J, Nowak G, Kleßen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226-29.
  • 35 Markwardt F, Huan X O, Fareed J, Walenga J M, Munch M, Hoppensteadt D. Pharmacokinetics of recombinant hirudin in primates. FASEB, Las Vegas. 1988
  • 36 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-88.
  • 37 Markwardt F, Klöcking H P, Sedlarik K, Drawert J. Tierexperimentelle Untersuchungen zur thrombolytischen Wirkung von Ocrase. Acta Biol Med Ger 1977; 36: 1315-27.
  • 38 Markwardt F, Landmann H. Blutgerinnungshemmende Proteine, Peptide und Aminosäurederivate. In: Handbook of Experimental Pharmacology. Vol. 27. Markwardt F. (ed). Berlin, Heidelberg: Springer; 1976: 76-142.
  • 39 Markwardt F, Nowak G, Hoffmann J. The influence of drugs on disseminated intravascular coagulation (DIC). II. Effects of naturally occurring and synthetic thrombin inhibitors. Thromb Res 1977; 11: 275-83.
  • 40 Markwardt F, Nowak G, Hoffmann J. Comparative study on thrombin inhibitors in experimental microthrombosis. Thromb Haemost 1983; 49: 235-37.
  • 41 Markwardt F, Nowak G, Stürzebecher J, Griessbach U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160-63.
  • 42 Markwardt F, Nowak G, Stürzebecher J, Vogel G. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393-400.
  • 43 Markwardt F, Nowak G, Stürzebecher J, Walsmann P. Studies on the pharmacokinetics of hirudin. Biomed Biochim Acta 1987; 46: 237-44.
  • 44 Markwardt F, Walsmann P. Die Reaktion zwischen Hirudin und Thrombin. HoppeSeyler’s Z Physiol Chem 1958; 312: 85-98.
  • 45 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombininhibitors Hirudin. Hoppe-Seyler’s Z Physiol Chem 1967; 348: 1381-86.
  • 46 Nowak G, Markwardt F. Influence of hirudin on endotoxin-induced disseminated intravascular coagulation (DIC) in weaned pigs. Exp Pathol 1980; 18: 438-43.
  • 47 Nowak G, Markwardt F, Fink E. Pharmacokinetic studies with recombinant hirudin in dogs. Folia Haematol 1988; 115: 70-74.
  • 48 Richter M, Cyranka U, Nowak G, Walsmann P. Pharmacokinetics of 125I-hirudin in rats and dogs. Folia Haematol 1988; 115: 64-69.
  • 49 Tripier D. Hirudin: a family of iso-proteins, isolation and sequence determination of new hirudins. Folia Haematol 1988; 115: 30-35.
  • 50 Vogel G, Markwardt F. Preliminary clinical reports on the antithrombotic action of hirudin (Abstr). Thromb Res (Suppl) 1987; 07: 42.
  • 51 Vogel G, Markwardt F. Clinical use of hirudin. Folia Haematol 1988; 115: 113-18.
  • 52 Walsmann P. Über den Einsatz des spezifischen Thrombininhibitors Hirudin für diagnostische und biochemische Untersuchungen. Pharmazie 1988; 43: 737-44.
  • 53 Walsmann P, Kaiser B. Biochemical and pharmacological properties of recombinant hirudin. Drugs of Today 1989; 25: 473-85.
  • 54 Walsmann P, Markwardt F. Biochemische und pharmakologische Aspekte des Thrombininhibitors Hirudin. Pharmazie 1981; 36: 653-60.
  • 55 Walsmann P, Markwardt F. On the isolation of the thrombin inhibitor hirudin. Thromb Res 1985; 40: 563-70.